Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Current Liabilities (2023 - 2025)

Contineum Therapeutics has reported Total Current Liabilities over the past 3 years, most recently at $6.4 million for Q3 2025.

  • Quarterly results put Total Current Liabilities at $6.4 million for Q3 2025, up 9.56% from a year ago — trailing twelve months through Sep 2025 was $6.4 million (up 9.56% YoY), and the annual figure for FY2024 was $10.0 million, up 81.87%.
  • Total Current Liabilities for Q3 2025 was $6.4 million at Contineum Therapeutics, down from $7.2 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CTNM hit a ceiling of $10.0 million in Q4 2024 and a floor of $3.7 million in Q2 2024.
  • Median Total Current Liabilities over the past 3 years was $6.3 million (2024), compared with a mean of $6.7 million.
  • Peak annual rise in Total Current Liabilities hit 92.94% in 2025, while the deepest fall reached 9.56% in 2025.
  • Contineum Therapeutics' Total Current Liabilities stood at $5.5 million in 2023, then skyrocketed by 81.87% to $10.0 million in 2024, then plummeted by 36.22% to $6.4 million in 2025.
  • The last three reported values for Total Current Liabilities were $6.4 million (Q3 2025), $7.2 million (Q2 2025), and $8.9 million (Q1 2025) per Business Quant data.